Modeyso
(Dordaviprone (ONC201))Phase 3Small molecule
Modeyso is one of 47 small molecule programs targeting Glioma. It is currently in Phase 3.
1
Indications
5
Total Trials
1
Active Trials
46
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
7
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
103 competitors in Glioma
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Paraplatin
AAvyxa
Phase 3
Voranigo
SServier
Phase 3
Ojemda
Day One BiopharmaceuticalsPhase 3
Opdivo
Bristol-Myers SquibbPhase 2
Keytruda
Merck & Co.Phase 2
Lynparza
AstraZenecaPhase 2
Verzenio
Eli LillyPhase 2
Dostarlimab
IncytePhase 2
Oncovin
Eli LillyPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Glioma3 trials
Regulatory
FDA Approval Timeline[4]
Aug 6, 2025
MODEYSO
NDA NDA219876
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dordaviprone (ONC201). EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]